Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2666844 | 0.80 | CYP3A4 (0.68) | CYP3A4TP53HSD17B10ALDH1A1TSHR | |
| SCHEMBL12618007 | 0.80 | CACNA1H (0.46) | ALDH1A1PDK2CYP1A2LMNACYP2D6 | |
| SCHEMBL973567 | 0.80 | PDK2 (0.48) | ALDH1A1PDK2CYP1A2LMNACYP2D6 | |
| SCHEMBL2666843 | 0.80 | PDK2 (0.38) | PDK2PIK3CDPIK3CAPIK3CBPI4KA | |
| SCHEMBL991922 | 0.76 | PDK2 (0.53) | ALDH1A1TSHRPDK2CA2CA1 | |
| SCHEMBL7375044 | 0.76 | PDK2 (0.53) | ALDH1A1PDK2LMNANPC1RAB9A | |
| SCHEMBL28849832 | 0.76 | CA2 (0.70) | CYP3A4TP53HSD17B10ALDH1A1TSHR | |
| SCHEMBL11840767 | 0.76 | LMNA (0.71) | CYP3A4TP53HSD17B10ALDH1A1TSHR | |
| SCHEMBL18291220 | 0.75 | PDK2 (0.49) | PDK2CA2CA1 | |
| SCHEMBL9072344 | 0.74 | GBA1 (0.36) | ALDH1A1PDK2LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119626-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-21 | — | — | US | disclosed |
| US-8119626-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20090291936-A1 | OXIME DERIVATIVE AND PREPARATIONS THEREOF | SUGAWARA KAZUTOSHI | 2009-11-26 | — | — | US | disclosed |
| US-20090291936-A1 | OXIME DERIVATIVE AND PREPARATIONS THEREOF | SUGAWARA KAZUTOSHI | 2009-11-26 | — | — | US | disclosed |
| US-7514439-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-7514439-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| WO-2007007886-A1 | AN OXIME DERIVATIVE AND PREPARATIONS THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | GCK, KHK, GCKR | CYP3A4 279/4885TP53 4391/4885HSD17B10 1208/4885 |
| US-20090291936-A1 | OXIME DERIVATIVE AND PREPARATIONS THEREOF | GCK, KHK, GCKR | CYP3A4 279/4885TP53 4391/4885HSD17B10 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.